Imunon, Inc. Increase (Decrease) in Contract with Customer, Liability
Imunon, Inc. (IMNN) reported Increase (Decrease) in Contract with Customer, Liability of -$500.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-19.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2021-03-19
- Imunon, Inc. increase (decrease) in contract with customer, liability for fiscal 2020 was -$500.00K.
- Imunon, Inc. increase (decrease) in contract with customer, liability for fiscal 2019 was -$500.00K.
- Imunon, Inc. increase (decrease) in contract with customer, liability for fiscal 2018 was -$500.00K.
- Imunon, Inc. increase (decrease) in contract with customer, liability for fiscal 2017 was -$500.00K.
| Period end | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|
| 2020-12-31 | -$500.00K 10-K · filed 2021-03-19 |
| 2019-12-31 | -$500.00K 10-K · filed 2021-03-19 |
| 2018-12-31 | -$500.00K 10-K · filed 2020-03-25 |
| 2017-12-31 | -$500.00K 10-K · filed 2019-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |